Devic disease: Translational medicine at work

Neurology

Volumn 82, Issue 15, 2014, Pages 1294-1295

  Rose John, Stefan ^a   Gold, Ralf ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; BETA INTERFERON; FINGOLIMOD; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NATALIZUMAB; PREDNISOLONE; RITUXIMAB; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CHRONIC PAIN; DISEASE ACTIVITY; EDITORIAL; HUMAN; HUMORAL IMMUNE DEFICIENCY; INTRACELLULAR SIGNALING; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; RHEUMATOID ARTHRITIS; DRUG ANTAGONISM; FEMALE; MALE; NOTE;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; NEUROMYELITIS OPTICA; RECEPTORS, INTERLEUKIN-6;

EID: 84902094466     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000322     Document Type: Editorial

References (11)

1. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-121. (Pubitemid 32201673)
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112. (Pubitemid 39626806)
3. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66: 630-643.
4. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012; 367: 115-123.
5. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011; 108: 3701-3706.
6. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121: 3375-3383.
7. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012; 52: 199-219.
8. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6: 383-392.
9. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 2014; 82: 1302-1306.
10. Ayzenberg I, Kleiter I, Schröder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013; 70: 394-397.
11. Andratsch M, Mair N, Constantin CE, et al. Reversal of cancer pain through anti-interleukin-6 treatment. J Neurosci 2009; 29: 13473-13483.